A Novel Prognostic Model for Oral Squamous Cell Carcinoma: The Functions and Prognostic Values of RNA-Binding Proteins

Yingjuan Lu¹,²,³†, Yongcong Yan¹,³,⁴†, Bowen Li¹,²,³, Mo Liu¹,², Yancan Liang¹,²,³, Yushan Ye¹,², Weiqi Cheng¹,², Jinsong Li¹,²*, Jiuyang Jiao¹,²* and Shaohai Chang¹,²*

¹ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ² Department of Oral and Maxillofacial Surgery, Sun Yat Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ³ RNA Biomedical Institute, Sun Yat Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴ Department of Hepatobiliary Surgery, Sun Yat Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Purpose: The biological roles and clinical significance of RNA-binding proteins (RBPs) in oral squamous cell carcinoma (OSCC) are not fully understood. We investigated the prognostic value of RBPs in OSCC using several bioinformatic strategies.

Materials and Methods: OSCC data were obtained from a public online database, the Limma R package was used to identify differentially expressed RBPs, and functional enrichment analysis was performed to elucidate the biological functions of the above RBPs in OSCC. We performed protein-protein interaction (PPI) network and Cox regression analyses to extract prognosis-related hub RBPs. Next, we established and validated a prognostic model based on the hub RBPs using Cox regression and risk score analyses.

Results: We found that the differentially expressed RBPs were closely related to the defense response to viruses and multiple RNA processes. We identified 10 prognosis-related hub RBPs (ZC3H12D, OAS2, INTS10, ACO1, PCBP4, RNASE3, PTGES3L-AARSD1, RNASE13, DDX4, and PCF11) and effectively predicted the overall survival of OSCC patients. The area under the receiver operating characteristic (ROC) curve (AUC) of the risk score model was 0.781, suggesting that our model exhibited excellent prognostic performance. Finally, we built a nomogram integrating the 10 RBPs. The internal validation cohort results showed a reliable predictive capability of the nomogram for OSCC.

Conclusion: We established a novel 10-RBP-based model for OSCC that could enable precise individual treatment and follow-up management strategies in the future.

Keywords: oral squamous cell carcinoma, RNA-binding proteins, prognostic model, bioinformatic tools, nomogram
INTRODUCTION

Oral cancer, comprising a group of tumors located in the alveolar ridge, buccal cavity, mucosa, floor of the mouth, palate, tongue, and other parts of the oral cavity, accounts for an estimated 350,000 new cases and 170,000 deaths per year worldwide. Of these, oral squamous cell carcinoma (OSCC) accounts for more than 95% of oral tumors. A major portion of global OSCC cases are diagnosed in Asia (1). Despite developments in the therapeutic strategies of OSCC that have been achieved over the last few years, the long-term survival rates of OSCC patients are still extremely low. Additionally, precise targeted therapies remain limited, resulting in treatment failure due to individual genetic differences and epigenetic changes among OSCC patients (2–4). Thus, a systematic study to identify key biomarkers for diagnosis and effective targets for treatment of OSCC is urgently needed.

Nomograms are statistics-based tools that can effectively integrate different variables and are widely used to detect prognostic factors for various cancers (5, 6). Many models have been established to predict the outcomes of OSCC by calculating the risk associated with clinicopathologic characteristics, such as age, sex, smoking status, TNM staging, and therapies (7, 8). Although these studies have enhanced our understanding of OSCC, few have taken into account genetic features, and these studies are not sufficiently accurate and reliable, as the underlying molecular mechanisms of OSCC might be considerably complex (9).

RNA-binding proteins (RBPs) modulate the functions of RNA transcripts at multiple levels (10). Currently, 1,542 RBPs have been identified, and more than 800 mRNAs have been discovered in human cells (11, 12). These RBPs bind RNA through globular RNA-binding domains (RBDs) and affect the splicing, stability, or translation of their target RNAs (13, 14). Considering the importance of RBPs in many cellular processes, it is not surprising that defects in their functions affect several human diseases, including neurological disorders, muscular atrophy, and cancer (15). Many studies have indicated that the dysregulation of RBPs is related to the biological behaviors of various cancer cells. For instance, human antigen R (HuR) is widely overexpressed in cancer cells and involved in posttranscriptional gene regulation (16). HuR not only affects lncRNAs but also binds to protein-coding mRNAs, exerting both positive and negative influences on their stability (17). The abnormal expression of heterogeneous nuclear ribonucleoprotein K (hnRNPK) is frequently observed in cancers and might play an important role in hepatocellular carcinoma (HCC) by changing the localization of MALAT1 (18). Serine/arginine-rich splicing factor 1 (SRSF1) is an RBP that is upregulated in glioma and plays an important role by regulating splicing, RNA stability, and nuclear export (19). Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) modulates oncogenic impact on regulating cell proliferation and apoptosis in HCC (20). Mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2) regulates transcript stability and exerts important effects in head and neck squamous cell carcinoma (HNSCC) (21). In summary, these previous studies have shown that RBPs may play important roles in tumorigenesis and tumor progression. However, only a few RBPs have been studied recently, and some RBPs were revealed to have critical functions in cancers.

In this study, we integrated all relevant OSCC information from The Cancer Genome Atlas (TCGA) database to perform a novel systematic analysis. To reveal the potential functions and clinical significance of RBPs in the pathogenesis of OSCC, we screened multiple differentially expressed RBPs in OSCC. Some of them may provide potential biomarkers for OSCC patients’ prognosis prediction.

MATERIALS AND METHODS

Dataset Collection and Identification of Differentially Expressed RBPs

The RNA sequencing data of 32 normal oral tissues and 331 OSCC tissues with corresponding clinical information were obtained from TCGA (https://portal.gdc.cancer.gov/). Approval of the institutional ethics committee was not necessary because the data were collected from publicly available online databases. To identify the differentially expressed genes between normal oral and OSCC tissue samples, all raw data were preprocessed using the Limma package. In addition, we also identified differentially expressed RBPs with a threshold of $|\log 2\text{-fold change}| \geq 1$ and a false discovery rate (FDR) <0.05. All TCGA patients were randomly divided into a training cohort with N*p (p = 2/3) samples and an internal validation cohort with N*q (q = 1/3) samples by caret R package. To validate our results responsibly, we searched for external validation cohort from Sun Yat-sen Memorial Hospital (n=58). This study was approved by the institutional review board of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University.

KEGG Pathway and GO Enrichment Analyses

The biological functions of differentially expressed RBPs were systematically detected by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The GO analysis included terms in the cellular component (CC), molecular function (MF), and biological process (BP) categories. All enrichment analyses were conducted by the WEB-based Gene Set Analysis Toolkit (WebGestalt, http://www.webgestalt.org/) (22). For both analyses, P values less than 0.05 and gene numbers greater than 5 were considered statistically significant.

PPI Network Construction and Module Screening

The protein-protein interactions (PPIs) among all differentially expressed RBPs were investigated using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (http://www.string-db.org/) (23). Cytoscape 3.8.0 software was used to further visualize the PPI network. The Molecular Complex Detection (MCODE) plug-in was used to select key modules and genes in the PPI network with both MCODE scores...
and node count numbers greater than 5 (24). A P value <0.05 was considered to indicate a significant difference.

**Prognosis-Related RBP Identification and Prognostic Model Construction**

We performed univariate Cox regression analysis on the differentially expressed RBPs in the critical modules of the training dataset using the survival R package. Subsequently, we performed a log-rank test to extract prognosis-related RBPs. Based on the above preliminarily screened significant candidate RBPs, a multivariate Cox proportional hazards regression model was further performed, and the risk score (RS) was calculated to predict the prognostic outcomes of OSCC patients (25). The RS formula for each sample was as follows: RS=Expressiongene1×βgene1+···+Expressiongenen×βgenen (where β is the regression coefficient derived from multivariate Cox regression). OSCC patients were divided into low-risk and high-risk groups according to the median RS analysis. The log-rank test was used to compare the difference in overall survival (OS) between the two groups. In addition, an internal validation cohort was used to test the predictive capability of the nomogram. Calibration curves were constructed using the rms R package to observe the accuracy of the prediction. A P value <0.05 indicated a significant difference.

**Verification of Express Level and Prognostic Significance by Immunohistochemistry (IHC)**

Fixed OSCC and adjacent normal tissues samples were sectioned at 4 µm thickness. The tissue samples were deparaffinized, subjected to antigen retrieval with sodium citrate, and incubated with 3% hydrogen peroxide for 15 min at room temperature. Then, they were blocked with goat serum for 15 min at 37°C and incubated with the indicated antibody at 4°C overnight. Subsequently, the secondary antibody was added and incubated for 1 h at room temperature. Finally, the sections were visualized with 3,3′-diaminobenzidine. The stained slides were scanned, and the images were then digitalized and analyzed using Image-Pro Plus 5.1 software.

**RESULTS**

**Identification of Differentially Expressed RBPs in OSCC**

Figure 1 shows the workflow of this study. RNA expression data and corresponding clinical information were downloaded from TCGA. In total, 331 OSCC samples and 32 normal oral samples were analyzed. The Limma R software package was used to preprocess these data and to identify differentially expressed...
RBPs (11). A total of 1,542 RBPs were analyzed in this study, and 257 met our inclusion criteria (P<0.05, |log2FC| >1.0), including 121 downregulated and 136 upregulated RBPs (Figure 2).

Functional Enrichment Analysis of the Differentially Expressed RBPs

The identified RBPs were divided into two groups, the upregulation group and the downregulation group, to explore their potential functions and mechanisms. The upregulated RBPs were significantly enriched in defense response to viruses and regulation of mRNA metabolic processes by GO and pathway analyses (Supplementary Table 1 and Figure 3A), while the downregulated RBPs were considerably enriched in mRNA processing, RNA splicing, and RNA catabolic processes (Supplementary Table 1 and Figure 3B). Additionally, the KEGG pathway analysis results showed that the upregulated RBPs were enriched in the RNA transport, spliceosome, and mRNA surveillance pathways (Supplementary Table 1 and Figure 3C), while the downregulated RBPs were mainly enriched in the RNA transport, ribosome, and mRNA surveillance pathways (Supplementary Table 1 and Figure 3D).

PPI Network Construction and Key Module Screening

To better understand the potential roles of these identified RBPs in OSCC, we constructed a PPI network using the STRING database and Cytoscape software. This PPI network consists of 228 nodes and 1,384 edges in total (Figure 4A). We further built the coexpression network using the MCODE plug-in and identified the key modules (Figure 4B). Of these, the first essential module, module 1, contained 49 nodes and 316 edges; the second module, module 2, consisted of 8 nodes and 28 edges; module 3 consisted of 13 nodes and 43 edges; module 4 consisted of 6 nodes and 12 edges; the next module consisted of 4 nodes and 6 edges; and the last module consisted of 16 nodes and 29 edges (Supplementary Figures 1A–F). The functional analysis showed that the RBPs in these key modules were enriched in mitochondrial translation, mitochondrial gene expression, and cellular protein complex disassembly (Supplementary Table 1).

Identification of Prognosis-Related RBPs

A total of 20 prognosis-associated candidate hub RBPs were identified by univariate Cox regression analysis (Supplementary Table 2). We further analyzed the candidate RBPs by multivariate Cox regression to determine their significance for prognosis. Ten hub RBPs—ZC3H12D, OAS2, INTS10, ACO1, PCBP4, RNASE3, PTGES3L-AARSD1, RNASE13, DDX4, and PCF11—were identified as independent predictors of OSCC (Supplementary Table 3). According to the expression profiles of 10 RBPs, cluster analysis was performed to analyze the 331 OSCC samples from the entire TCGA cohort, and two subtypes were determined, which demonstrates associated heterogeneity can be effectively identified by 10 RBPs model (Supplementary Figure 2A). Subsequently, the result of principal component analysis (PCA) indicates that 10 RBPs can distinguish OSCC patients in training cohort, validation cohort, and entire TCGA cohort (Supplementary Figures 2B–D).

Prognosis-Related Genetic RS Model Construction and Validation

The 10 hub RBPs were used to build a prognostic model. To assess the predictive ability of this model, we further carried out an RS analysis in the training cohort. The RS of each patient was calculated according to the following formula: RS=ZC3H12D*-1.505+OAS2*-0.006+INTS10*-0.135+ACO1*0.108+PCBP4*-0.122+RNASE3*2.757+PTGES3L-AARSD1*2.827+RNASE13*-11.340+DDX4*8.283+PCF11*-0.204. A total of 221 OSCC patients were divided into low-risk and high-risk groups according to the median RS. The results showed that patients in the low-risk group had significantly longer OS times than those in the high-risk group.

FIGURE 2 | The differentially expressed RBPs in OSCC. (A) Hierarchical clustering of OSCC tissues and normal tissues by differentially expressed RBPs. The upper horizontal axis represents samples, and the left vertical axis represents clusters of RBPs. Red represents upregulated RBPs, and green represents downregulated RBPs. (B) Volcano plot of differentially expressed RBPs. The red dots represent upregulated RBPs, and the green dots represent downregulated RBPs. FC, Fold Change; fdr, false discovery rate.
Time-dependent ROC curve analysis was further conducted to estimate the prognostic ability of the identified RBPs. The area under the ROC curve (AUC) of the RS model was 0.781 (Figure 5B), which suggested that our model has high prognostic accuracy. The expression heat map of the 10 prognostic RBPs is illustrated in Figure 5C, and the RS and survival status for the low- and high-risk groups are displayed in Figure 5D. Moreover, the results from our internal validation cohort, using
the same formula used to assess the predictive capability of the 10-gene prognostic model, showed that patients with lower RSs had better OS (Figures 6A–D). These results indicated that the prognostic model has significant predictive capability.

**Prognostic Value of Different Clinical Parameters**

To assess the prognostic significance of different clinical features, we performed a univariate Cox regression analysis of OSCC patients in the training set and internal validation set. The results showed that stage, grade, age, and RS were correlated with the OS of OSCC patients in both cohorts (P<0.05) (Figures 7A, B), whereas only stage and RS were independent prognostic factors for OS in the multiple regression analysis of both cohorts (P<0.05) (Figures 7C, D).

**Development and Validation of a Nomogram Based on the Hub RBPs**

Based on the multivariate analysis results, a nomogram was established to predict the 1-, 2-, and 3-year OS (Figure 8A). We list the points for each independent prognostic factor in the
nomogram and summed them to obtain the total point value, which was drawn on the bottom scale. We plotted the calibration curves, which indicated no apparent deviation from the ideal line, indicating our model might be effectively used to predict outcomes and survival rates of OSCC patients (Figures 8B, C).

Next, the protein expression pattern of 10 RBPs in the prognosis model were analyzed in the tissues of OSCC patients from Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. The results demonstrated that the expression of the ZC3H12D, OAS2, INTS10, PCBP4, RNASE13, PCF11 protein were low expressed in OSCC tissues than that in normal tissues. ACO1, DDX4, PTGES3L-AARSD1, RNASE3 were high expressed in OSCC tissues than that in normal tissues (Supplementary Figure 3).

FIGURE 6 | Risk score analysis of 10-gene prognostic model in the internal validation cohort. (A) Survival curves for OS in low- and high-risk subgroups; (B) ROC curves for predicting OS based on risk score; (C) Expression heat map of 10 prognostic RBPs in low- and high-risk subgroups; (D) Risk score distribution and survival status for low- and high-risk subgroups. OS, overall survival; ROC, receiver operating characteristic.

DISCUSSION

The survival rate of OSCC patients remains low because there are limited prognostic factors that can provide effective targeted therapies and precisely predict outcomes (9). Previous studies have demonstrated that RBPs, which regulate oncogene expression at the posttranscriptional level, significantly affect
tumorigenesis and progression, indicating that RBPs are potential cancer biomarkers (27, 28). In fact, several RBPs have been identified to predict OS in cancer. Zhao et al. identified a novel extra-ribosomal role of RPS3 as a potential therapeutic target in HCC via the posttranscriptional regulation of SIRT1 expression (29). Soni et al. highlighted that MK2, as the master regulator of RBPs, plays an important role in the regulation of transcript stability and tumor progression, as well as the possibility of the use of MK2 as a therapeutic target in tumor management (30). However, the role of RBPs in OSCC is not well understood, even though studies have focused on the functions of RBPs in head and neck carcinoma. Berggen et al. revealed that MK2 could be a potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate radiation resistance in HNSCC (31). Jiang et al. indicated that LINC00460 is a promising candidate prognostic predictor for HNSCC because it facilitates the entry of an RBP called PRDX1 into the nucleus and promotes the epithelial-mesenchymal transition (EMT) in HNSCC cells (32). However, most of these studies analyzed the functions of single RBPs, while prognostic markers including several RBPs should be collectively investigated (33).

In the present study, we identified dysregulated RBPs in OSCC based on TCGA database and systematically analyzed the related biological pathways of these RBPs. We further constructed a PPI network to identify the key modules that may have significant impact on the prognosis of OSCC. We identified 10 hub RBPs by constructing a PPI network and performing Cox regression analysis, inducing ZC3H12D, OAS2, INTS10, ACO1, PCBP4, RNASE3, PTGES3L-AARSD1, RNASE13, DDX4, and PCF11. Most of these RBPs are associated with tumorigenesis and cancer progression, including OAS2.
Of these, OAS2, an interferon (IFN)-induced antiviral enzyme, has been reported as an OSCC-related gene. Similarly, Wang et al. analyzed three microarray datasets and found that OAS2 expression was closely related to the survival rate of patients with oral cancer (46), which was consistent with our results. Interestingly, the IFN system is a central and powerful host first-line antiviral defense strategy that is inhibited by HPV16 in HNSCC (47). A substantial OAS2 level can activate the IFN signaling pathway and in turn produce a T-cell response that is effective in clearing HPV infection (48). Thus, OAS2 may serve as a key regulator and may provide rational insight into immunotherapy for HPV-associated OSCC. However, the detailed mechanisms underlying these hub RBPs in OSCC are still unexplored, and further in-depth studies to discover their potential roles would be valuable.

Subsequently, we established a risk model including the 10 hub RBPs. The ROC analysis revealed that these 10 genes had a good diagnostic capability to identify OSCC patients with a poor prognosis. Next, a prognostic nomogram was built to predict
OSCC patients’ survival. Finally, calibration curves were plotted to detect the prognostic value of the 10 RBP coding genes, and the results indicated that the nomogram-predicted outcomes were consistent with the actual survival rates.

To sum up, all the evidence suggested that our prognostic model including 10 RBPs has a certain value for the treatment decisions of OSCC patients. Nonetheless, there are still several limitations in our study. The main one is the lack of clinical data. Survival analysis included only basic clinical factors which are obtained from TCGA database. However, as we have known, other factors, such as the HPV status of patients, may affect the reliability of the Cox regression analysis. In addition, the results of functional enrichment analysis in this study have suggested that some RBPs may affect the outcome of OSCC patients through interactions with virus. If we have more clinical information, we were able to have a better understanding of combinations between RBPs and HPV infection. Another limitation lies in the expression of all genes from TCGA cohort was detected in an OSCC tissue sample from one patient. But OSCC is an extremely heterogeneous tumor at both genetic and molecular levels. In the future, clinical trials are needed. More analysis in multiple OSCC specimens from one patient should be applied to confirm our results. Besides, cooperation with other hospitals is also needed to enlarge the clinical sample size for model validation.

CONCLUSION

We systematically explored the prognostic value of differentially expressed RBPs by performing a series of bioinformatics analyses on OSCC. A prognostic model of the 10 hub RBPs was constructed and further validated. Our results were used to establish a novel prognostic model for OSCC and will contribute new candidate markers to aid in therapeutic decision-making in the future.

ETHICS STATEMENT

For TCGA database, approval of the institutional ethics committee was not necessary because the data were collected from publicly available online databases. For external validation cohort, all procedures were approved by the institutional ethics committee of Sun Yat-Sen Memorial Hospital, and informed consent was obtained from all patients.

AUTHOR CONTRIBUTIONS

Conception and design: YLu and YYa. Development of methodology: YLu and YYa. Analysis and interpretation of data (e.g., statistical analysis, bioinformatics analysis): YLu, YYa, BL, ML, and YLi. Writing, review, and/or revision of the manuscript: YLu, YYa, BL, ML, YLi, YYe, WC, JJ, JL, and SC. Administrative, technical, or material support (i.e., reporting or organizing data): YLu, BL, ML, YLi, JL, JJ, and SC. Study supervision: JL, JJ, and SC. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.592614/full#supplementary-material

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018. Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492.
2. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.
3. Aragir A, Karamouzis MV, Raben D, Ferris RL. Head and Neck Cancer. Lancet (2008) 371(9625):1695–709. doi: 10.1016/S0140-6736(08)60728-X.
4. Liu X, Zhao X, Gou C. Identification of Novel Methylated DNA Marker ZNF569 for Head and Neck Squamous Cell Carcinoma. J Cancer (2019) 10 (10):2250–60. doi: 10.7150/jca.31156

FUNDING

This work was supported by the National Natural Science Foundation of China (NSFC; 81900959 to YLu, 81802700 to YLi, 82072990 and 81872194 to JL).

AUTHOR’S NOTE

This manuscript has been released as a preprint at ResearchSquare.
5. Wang K, Li L, Fu L, Yuan Y, Dai H, Zhu T, et al. Integrated Bioinformatics Analysis the Function of RNA Binding Proteins (RBPs) and Their Prognostic Value in Breast Cancer. *Front Pharmacol* (2019) 10:140. doi: 10.3389/fphar.2019.00140

6. Li W, Li X, Gao LN, You CG. Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins in Lung Squamous Cell Carcinoma. *Front Genet* (2020) 11:185. doi: 10.3389/fgene.2020.00185

7. Wang F, Zhang H, Wen J, Zhou J, Liu Y, Cheng B, et al. Nomograms Forecasting Long-Term Overall and Cancer-Specific Survival of Patients With Oral Squamous Cell Carcinoma. *Cancer Med* (2018) 7(4):943–52. doi: 10.1002/cam4.1216

8. Chen F, Lin L, Liu F, Yan L, Qiu Y, Wang J, et al. Three Prognostic Indexes as Predictors of Response to Adjunct Chemoradiotherapy in Patients With Oral Squamous Cell Carcinoma After Radical Surgery: A Large-Scale Prospective Study. *Head Neck* (2019) 41(2):301–8. doi: 10.1002/hed.25495

9. Mattavelli D, Lombardi D, Missale F, Calza S, Batocchio S, Paderno A, et al. Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio. *Front Oncol* (2019) 9:339. doi: 10.3389/fonc.2019.00339

10. Nahalka J. The Role of the Protein-RNA Recognition Code in Neurodegeneration. *Cell Mol Life Sci* (2019) 76(11):2043–58. doi: 10.1007/s00018-019-03096-3

11. Gersterber S, Hafner M, Tuschl T. A Census of Human RNA-Binding Proteins. *Nat Rev Genet* (2014) 15(12):329–45. doi: 10.1038/nrg3813

12. Kecharvzi A, Jang SC. Dissecting the Expression Landscape of RNA-Binding Proteins in Human Cancers. *Genome Biol* (2014) 15(1):R14. doi: 10.1186/gb-2014-15-1-r14

13. Masuda K, Kuwano Y. Diverse Roles of RNA-Binding Proteins in Cancer Traits and Their Implications in Gastrointestinal Cancers. *Wiley Interdiscip Rev* RNA (2019) 10(3):e1520. doi: 10.1002/wrrn.1520

14. Lunde BM, Moore C, Varani G. RNA-Binding Proteins: Modular Design for Efficient Function. *Nat Rev Mol Cell Biol* (2007) 8(6):479–90. doi: 10.1038/nrm2178

15. Castello A, Fischer B, Hentze MW, Preiss T. RNA-Binding Proteins in Mendelian Disease. *Trends Genet* (2013) 29(5):318–27. doi: 10.1016/j.tig.2013.01.004

16. Wang E, Aifantis I. RNA Splicing and Cancer [Published Online Ahead of Print, 2020 May 17]. *Trends Cancer* (2020) 6:2045–63. doi: 10.1016/j.trecan.2020.04.011

17. Hu YP, Jin YP, Wu XS, Yang Y, Li YS, Li HF, et al. LncRNA-HGBC Stabilized by HuR Promotes Gallbladder Cancer Progression by Regulating miR-502-3p. *Mol Cancer* (2017) 16(9):849–90. doi: 10.1186/s12943-016-0527-9

18. Li W, Li X, Gao LN, Song PP, You CG. Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Lung Adenocarcinoma. *Aging (Albany NY)* (2020) 12(4):3558–73. doi: 10.18632/aging.202828

19. Hu Q, Peng J, Chen X, Li H, Song M, Cheng B, et al. Obesity and Genes Related to Lipid Metabolism Predict Poor Survival in Oral Squamous Cell Carcinoma. *Oral Oncol* (2019) 89:14–22. doi: 10.1016/j.oraloncology.2018.12.006

20. Liu S, Shi L, Yang X, Wang T, Dong C, Guo W, et al. Nuclear Survivin Promoted by Acetylation Is Associated With the Aggressive Phenotype of Oral Squamous Cell Carcinoma. *Cell Cycle* (2017) 16(9):894–902. doi: 10.1080/15384101.2017.1310352

21. Li M, Gao F, Yu X, Zhao Q, Zhou L, Liu W, et al. Promotion of Ubiquitination-Dependent Survivin Destruction Contributes to Xanthohumol-Mediated Tumor Suppression and Overcomes Radioresistance in Human Oral Squamous Cell Carcinoma. *J Exp Clin Cancer Res* (2020) 39(1):88. doi: 10.1186/s13046-020-11593-2

22. Liao Y, Si L, Zhai Y, Hu Y, Hu Z, Bei J, et al. Genome-Wide Association Study Identifies 8p21.3 Associated With Persistent Hepatitis B Virus Infection Among Chinese. *Nat Commun* (2016) 7:11664. doi: 10.1038/ncomms11664

23. Gonzalez-Sanchez L, Cobos-Fernandez MA, Lopez-Nieva P, Villa-Morales M, Stamatialis K, Cueva JM, et al. Exploiting the Passenger AC01-Deficiency Arising From 9p21 Deletions to Kill T-Cell Lymphoblastic Neoplasia Cells. *Carcinogen* (2020) 41(8):1113–22. doi: 10.1093/carcin/bgz185

24. Pio R, Zodaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, et al. Alpha CP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not its
Alternative Splice Variant Alpha CP-4a, Is Underexpressed in Lung Cancer. 
Cancer Res (2004) 64(12):4171–9. doi: 10.1158/0008-5472.CAN-03-2982

44. Schudrowitz N, Takagi S, Wessel GM, Yasima M. Germline Factor DDX4 Functions in Blood-Derived Cancer Cell Phenotypes. Cancer Sci (2017) 108(8):1612–9. doi: 10.1111/cas.13299

45. Ogorodnikov A, Levin M, Tattikota S, Tokalov S, Hoque M, Scherzinger D, et al. Transcriptome 3'end Organization by PCF11 Links Alternative Polyadenylation to Formation and Neuronal Differentiation of Neuroblastoma. Nat Commun (2018) 9(1):5331. doi: 10.1038/s41467-018-07580-5

46. Wang J, Wang Y, Kong F, Han R, Song W, Chen D, et al. Identification of a Six-Gene Prognostic Signature for Oral Squamous Cell Carcinoma. J Cell Physiol (2020) 235(3):3056–68. doi: 10.1002/jcp.29210

47. Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, et al. Mitigating SOX2-Potential Immune Escape of Head and Neck Squamous Cell Carcinoma With a STING-Inducing Nanosatellite Vaccine. Clin Cancer Res (2018) 24(17):4242–55. doi: 10.1158/1078-0432.CCR-17-2807

48. Luckau S, Wehrs TP, Brandau S, Horn PA, Lindemann M. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells. J Immunother (2016) 39(8):316–20. doi: 10.1097/CJI.000000000000137

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer WW declared a shared affiliation, with no collaboration, with the authors to the handling editor at the time of review.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Lu, Yan, Li, Liu, Liang, Ye, Cheng, Li, Jiao and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.